Healthcare Global Enterprises Ltd
Healthcare Global Enterprises Ltd is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector.[1]
- Market Cap ₹ 7,069 Cr.
- Current Price ₹ 507
- High / Low ₹ 568 / 310
- Stock P/E 127
- Book Value ₹ 61.8
- Dividend Yield 0.00 %
- ROCE 8.92 %
- ROE 4.78 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 29.4% CAGR over last 5 years
Cons
- Stock is trading at 8.30 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 2.10% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of BSE Allcap Nifty Total Market Nifty Microcap 250 BSE SmallCap BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
338 | 451 | 519 | 584 | 700 | 829 | 976 | 1,092 | 1,009 | 1,395 | 1,691 | 1,908 | 2,132 | |
292 | 413 | 443 | 499 | 595 | 713 | 864 | 936 | 887 | 1,161 | 1,394 | 1,581 | 1,759 | |
Operating Profit | 47 | 38 | 76 | 85 | 105 | 116 | 112 | 157 | 122 | 234 | 297 | 327 | 374 |
OPM % | 14% | 9% | 15% | 15% | 15% | 14% | 11% | 14% | 12% | 17% | 18% | 17% | 18% |
2 | 3 | 0 | -2 | 10 | 25 | 10 | 10 | -72 | 110 | 15 | 24 | 34 | |
Interest | 29 | 32 | 34 | 38 | 23 | 42 | 70 | 138 | 119 | 98 | 104 | 109 | 137 |
Depreciation | 30 | 36 | 39 | 44 | 57 | 71 | 85 | 148 | 159 | 158 | 163 | 174 | 199 |
Profit before tax | -10 | -27 | 3 | 0 | 35 | 27 | -33 | -119 | -229 | 88 | 45 | 68 | 72 |
Tax % | 7% | 20% | -56% | -730% | 34% | 38% | -7% | 5% | -3% | 56% | 61% | 39% | |
-11 | -32 | 5 | 2 | 23 | 17 | -31 | -125 | -221 | 39 | 18 | 41 | 66 | |
EPS in Rs | -1.54 | -5.21 | 0.12 | -0.17 | 2.59 | 2.36 | -2.82 | -12.03 | -15.43 | 3.87 | 2.11 | 3.46 | 4.19 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 14% |
3 Years: | 24% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 29% |
3 Years: | 33% |
TTM: | 137% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 36% |
3 Years: | 28% |
1 Year: | 52% |
Return on Equity | |
---|---|
10 Years: | -3% |
5 Years: | -5% |
3 Years: | 2% |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 67 | 68 | 70 | 85 | 86 | 87 | 88 | 89 | 125 | 139 | 139 | 139 | 139 |
Reserves | 217 | 196 | 210 | 341 | 347 | 428 | 389 | 293 | 572 | 731 | 721 | 686 | 722 |
308 | 292 | 349 | 324 | 420 | 464 | 658 | 1,347 | 977 | 915 | 901 | 1,274 | 1,558 | |
116 | 133 | 147 | 294 | 372 | 461 | 515 | 518 | 357 | 433 | 549 | 601 | 647 | |
Total Liabilities | 708 | 688 | 776 | 1,043 | 1,225 | 1,440 | 1,650 | 2,246 | 2,031 | 2,218 | 2,311 | 2,701 | 3,067 |
508 | 512 | 528 | 583 | 685 | 828 | 970 | 1,646 | 1,382 | 1,547 | 1,553 | 1,758 | 2,091 | |
CWIP | 0 | 11 | 42 | 121 | 148 | 174 | 153 | 46 | 30 | 22 | 18 | 83 | 36 |
Investments | 61 | 2 | 0 | 64 | 11 | 53 | 49 | 34 | 26 | 9 | 10 | 10 | 11 |
139 | 164 | 205 | 275 | 381 | 385 | 478 | 520 | 593 | 641 | 730 | 850 | 929 | |
Total Assets | 708 | 688 | 776 | 1,043 | 1,225 | 1,440 | 1,650 | 2,246 | 2,031 | 2,218 | 2,311 | 2,701 | 3,067 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
31 | 51 | 60 | 73 | 91 | 98 | 98 | 130 | 121 | 220 | 252 | 285 | |
-178 | -12 | -79 | -204 | -210 | -283 | -238 | -101 | -171 | 125 | -133 | -226 | |
140 | -27 | 22 | 216 | 89 | 161 | 84 | -58 | 112 | -155 | -140 | -64 | |
Net Cash Flow | -7 | 13 | 2 | 85 | -29 | -24 | -56 | -30 | 62 | 190 | -22 | -5 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 65 | 43 | 45 | 43 | 54 | 57 | 59 | 62 | 67 | 57 | 65 | 56 |
Inventory Days | 35 | 33 | 36 | 32 | 40 | 46 | 45 | 35 | 32 | 31 | 33 | 33 |
Days Payable | 186 | 193 | 208 | 264 | 272 | 274 | 303 | 234 | 221 | 199 | 214 | 216 |
Cash Conversion Cycle | -86 | -117 | -127 | -188 | -178 | -171 | -200 | -136 | -121 | -112 | -116 | -127 |
Working Capital Days | -4 | -20 | -44 | -72 | -90 | -73 | -92 | -70 | 33 | -21 | -22 | -26 |
ROCE % | 4% | 1% | 7% | 6% | 7% | 6% | 3% | 1% | -1% | 5% | 8% | 9% |
Documents
Announcements
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations
1d - Open offer for acquisition of equity shares by Hector Asia Holdings.
-
Detailed Public Statement
1d - Open offer for acquisition of 26% shares in HCG.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
27 Feb - Earnings call discussing Q3 results held on Feb 27, 2025.
-
Disclosure under Regulation 30A of LODR
25 Feb - Earnings call scheduled for February 27, 2025.
-
Integrated Filing (Financial)
24 Feb - Integrated financial filing for Q4 2024 results.
Annual reports
Concalls
-
Feb 2025TranscriptNotesPPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Oct 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Sep 2020Transcript PPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
Jun 2019TranscriptPPT
-
May 2019TranscriptNotesPPT
-
Feb 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
May 2018Transcript PPT
-
Feb 2018TranscriptPPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016Transcript PPT
-
Jun 2016Transcript PPT
Service Offering
The Company is a provider of specialty healthcare focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centers licensed by the AERB. It also provides fertility treatment under our “Milann” brand. [1]